Development of novel tumor-specific PLGA microbubble ultrasound contrast media

2014 Fiscal Year Final Research Report

• Project/Area Number: 24591809
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Gunma University
• Principal Investigator: TSUSHIMA Yoshito 群馬大学, 医学(系)研究科(研究院), 教授 (20375546)
• Research Collaborator: ACHMAD Arifudin 群馬大学, 大学院医学系研究科放射線診断核医学分野, 助教 (30757381)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 超音波断層法 / 超音波造影剤 / マイクロバブル / 抗EGFR抗体 / Cetuximab / drug-delivery agent

Outline of Final Research Achievements

The aim of this study was to develop a novel ultrasound contrast media which specifically accumulates into malignant tumors, and also acts as a drug-delivery agent. After several attempts, Cetuximab-labelled nanobubble (CTX-NB) was successfully synthesized. Cetuximab is the monoclonal antibody to the epidermal growth factor receptor (EFGR). CTX-NB has a shell of Poly-D,L-lactide-co-glycolide (PLGA), and contains perfluorooctyl bromide (PFOB). Specific accumulation and internalization of CTX-NB were microscopically confirmed in vitro using cultured EFGR-positive MDA-MB-231 human breast cancer cells.

Free Research Field

放射線診断学